203 related articles for article (PubMed ID: 18851881)
1. The performance of docetaxel-loaded solid lipid nanoparticles targeted to hepatocellular carcinoma.
Xu Z; Chen L; Gu W; Gao Y; Lin L; Zhang Z; Xi Y; Li Y
Biomaterials; 2009 Jan; 30(2):226-32. PubMed ID: 18851881
[TBL] [Abstract][Full Text] [Related]
2. Docetaxel (DTX)-loaded polydopamine-modified TPGS-PLA nanoparticles as a targeted drug delivery system for the treatment of liver cancer.
Zhu D; Tao W; Zhang H; Liu G; Wang T; Zhang L; Zeng X; Mei L
Acta Biomater; 2016 Jan; 30():144-154. PubMed ID: 26602819
[TBL] [Abstract][Full Text] [Related]
3. The characteristics and performance of a multifunctional nanoassembly system for the co-delivery of docetaxel and iSur-pDNA in a mouse hepatocellular carcinoma model.
Xu Z; Zhang Z; Chen Y; Chen L; Lin L; Li Y
Biomaterials; 2010 Feb; 31(5):916-22. PubMed ID: 19846217
[TBL] [Abstract][Full Text] [Related]
4. Enhanced antitumor efficacy, biodistribution and penetration of docetaxel-loaded biodegradable nanoparticles.
Liu Q; Li R; Zhu Z; Qian X; Guan W; Yu L; Yang M; Jiang X; Liu B
Int J Pharm; 2012 Jul; 430(1-2):350-8. PubMed ID: 22525076
[TBL] [Abstract][Full Text] [Related]
5. Preparation, characterization, and antitumor activities of folate-decorated docetaxel-loaded human serum albumin nanoparticles.
Jiang S; Gong X; Zhao X; Zu Y
Drug Deliv; 2015 Feb; 22(2):206-13. PubMed ID: 24471890
[TBL] [Abstract][Full Text] [Related]
6. Superior antitumor efficiency of cisplatin-loaded nanoparticles by intratumoral delivery with decreased tumor metabolism rate.
Li X; Li R; Qian X; Ding Y; Tu Y; Guo R; Hu Y; Jiang X; Guo W; Liu B
Eur J Pharm Biopharm; 2008 Nov; 70(3):726-34. PubMed ID: 18634874
[TBL] [Abstract][Full Text] [Related]
7. Tumor targetability and antitumor effect of docetaxel-loaded hydrophobically modified glycol chitosan nanoparticles.
Hwang HY; Kim IS; Kwon IC; Kim YH
J Control Release; 2008 May; 128(1):23-31. PubMed ID: 18374444
[TBL] [Abstract][Full Text] [Related]
8. Docetaxel-loaded-lipid-based-nanosuspensions (DTX-LNS): preparation, pharmacokinetics, tissue distribution and antitumor activity.
Wang L; Liu Z; Liu D; Liu C; Juan Z; Zhang N
Int J Pharm; 2011 Jul; 413(1-2):194-201. PubMed ID: 21540085
[TBL] [Abstract][Full Text] [Related]
9. Ceramide and N,N,N-Trimethylphytosphingosine-Iodide (TMP-I)-Based Lipid Nanoparticles for Cancer Therapy.
Balakrishnan P; Song CK; Jahn A; Cho HJ
Pharm Res; 2016 Jan; 33(1):206-16. PubMed ID: 26337769
[TBL] [Abstract][Full Text] [Related]
10. Tumor specific delivery and therapy by double-targeted nanostructured lipid carriers with anti-VEGFR-2 antibody.
Liu D; Liu F; Liu Z; Wang L; Zhang N
Mol Pharm; 2011 Dec; 8(6):2291-301. PubMed ID: 21923159
[TBL] [Abstract][Full Text] [Related]
11. Development of a weak-base docetaxel derivative that can be loaded into lipid nanoparticles.
Zhigaltsev IV; Winters G; Srinivasulu M; Crawford J; Wong M; Amankwa L; Waterhouse D; Masin D; Webb M; Harasym N; Heller L; Bally MB; Ciufolini MA; Cullis PR; Maurer N
J Control Release; 2010 Jun; 144(3):332-40. PubMed ID: 20202473
[TBL] [Abstract][Full Text] [Related]
12. Docetaxel-loaded solid lipid nanoparticles suppress breast cancer cells growth with reduced myelosuppression toxicity.
Yuan Q; Han J; Cong W; Ge Y; Ma D; Dai Z; Li Y; Bi X
Int J Nanomedicine; 2014; 9():4829-46. PubMed ID: 25378924
[TBL] [Abstract][Full Text] [Related]
13. Transarterial chemoembolization using docetaxel-loaded phytantriol cubic phase precursor for the treatment of hepatocellular carcinoma.
Han K; Wang Z; Peng X; Chen B; Wen X; Dong Y; Wu C
J Pharm Sci; 2011 Jun; 100(6):2240-7. PubMed ID: 21491445
[TBL] [Abstract][Full Text] [Related]
14. Antitumor effects of hyaluronic acid inhibitor 4-methylumbelliferone in an orthotopic hepatocellular carcinoma model in mice.
Piccioni F; Malvicini M; Garcia MG; Rodriguez A; Atorrasagasti C; Kippes N; Piedra Buena IT; Rizzo MM; Bayo J; Aquino J; Viola M; Passi A; Alaniz L; Mazzolini G
Glycobiology; 2012 Mar; 22(3):400-10. PubMed ID: 22038477
[TBL] [Abstract][Full Text] [Related]
15. Anti-tumor effects of polybutylcyanoacrylate nanoparticles of diallyl trisulfide on orthotopic transplantation tumor model of hepatocellular carcinoma in BALB/c nude mice.
Zhang ZM; Yang XY; Deng SH; Xu W; Gao HQ
Chin Med J (Engl); 2007 Aug; 120(15):1336-42. PubMed ID: 17711740
[TBL] [Abstract][Full Text] [Related]
16. Glycyrrhizin-modified O-carboxymethyl chitosan nanoparticles as drug vehicles targeting hepatocellular carcinoma.
Shi L; Tang C; Yin C
Biomaterials; 2012 Oct; 33(30):7594-604. PubMed ID: 22796165
[TBL] [Abstract][Full Text] [Related]
17. Cellular cytotoxicity and in-vivo biodistribution of docetaxel poly(lactide-co-glycolide) nanoparticles.
Esmaeili F; Dinarvand R; Ghahremani MH; Ostad SN; Esmaily H; Atyabi F
Anticancer Drugs; 2010 Jan; 21(1):43-52. PubMed ID: 19809300
[TBL] [Abstract][Full Text] [Related]
18. Targeting docetaxel-PLA nanoparticles simultaneously inhibit tumor growth and liver metastases of small cell lung cancer.
Liang Z; Yang N; Jiang Y; Hou C; Zheng J; Shi J; Zhang R; Li D; Liu Y; Zuo P
Int J Pharm; 2015 Oct; 494(1):337-45. PubMed ID: 26299762
[TBL] [Abstract][Full Text] [Related]
19. Development of docetaxel-loaded intravenous formulation, Nanoxel-PM™ using polymer-based delivery system.
Lee SW; Yun MH; Jeong SW; In CH; Kim JY; Seo MH; Pai CM; Kim SO
J Control Release; 2011 Oct; 155(2):262-71. PubMed ID: 21704664
[TBL] [Abstract][Full Text] [Related]
20. Green tea catechins augment the antitumor activity of doxorubicin in an in vivo mouse model for chemoresistant liver cancer.
Liang G; Tang A; Lin X; Li L; Zhang S; Huang Z; Tang H; Li QQ
Int J Oncol; 2010 Jul; 37(1):111-23. PubMed ID: 20514403
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
